Ezetimibe + other lipid-lowering medication(s) (DrugBank: Ezetimibe)
1 disease| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 260 | シトステロール血症 | 2 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT00705211 (ClinicalTrials.gov) | June 2007 | 23/6/2008 | A 52-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05245) | Designated Drug Use Investigation (Long-Term Administration) of Zetia 10-mg Tablets - A 52-Week Long-Term Designated Drug Use Investigation of Zetia Monotherapy and Combination Therapy | Hypercholesterolemia;Familial Hypercholesterolemia;Homozygous Sitosterolemia | Drug: Ezetimibe;Drug: Ezetimibe + other lipid-lowering medication(s) | Merck Sharp & Dohme Corp. | Bayer | Completed | N/A | N/A | Both | 1794 | N/A | NULL |
| 2 | NCT00704444 (ClinicalTrials.gov) | June 2007 | 23/6/2008 | A 12-week Post-marketing, Observational Study to Confirm the Safety and Efficacy of Zetia Alone or in Combination With Other Lipid-lowering Drugs in Japanese Subjects With Hypercholesterolemia (Study P05244) | Designated Drug Use Investigation (12 Weeks) of Zetia 10mg Tablets - A 12-Week Designated Drug Use Investigation of Zetia Monotherapy and Combination Therapy | Hypercholesterolemia;Familial Hypercholesterolemia;Homozygous Sitosterolemia | Drug: Ezetimibe;Drug: Ezetimibe + other lipid-lowering medication(s) | Merck Sharp & Dohme Corp. | Bayer | Completed | N/A | N/A | Both | 11332 | N/A | NULL |